Gwenn Hansen
2023
In 2023, Gwenn Hansen earned a total compensation of $1.6M as Chief Scientific Officer at Nurix Therapeutics, a 57% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,693 |
|---|---|
| Option Awards | $670,084 |
| Salary | $493,200 |
| Stock Awards | $259,920 |
| Other | $5,860 |
| Total | $1,632,757 |
Hansen received $670.1K in option awards, accounting for 41% of the total pay in 2023.
Hansen also received $203.7K in non-equity incentive plan, $493.2K in salary, $259.9K in stock awards and $5.9K in other compensation.
Rankings
In 2023, Gwenn Hansen's compensation ranked 714th out of 3,006 executives tracked by ExecPay. In other words, Hansen earned more than 76.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 714 out of 3,006 | 76th |
Division Manufacturing | 406 out of 1,650 | 75th |
Major group Chemicals And Allied Products | 276 out of 918 | 70th |
Industry group Drugs | 270 out of 881 | 69th |
Industry Pharmaceutical Preparations | 175 out of 637 | 73rd |
Source: SEC filing on March 27, 2024.
Hansen's colleagues
We found two more compensation records of executives who worked with Gwenn Hansen at Nurix Therapeutics in 2023.
News
Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
March 27, 2024
Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
March 24, 2023
Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
March 25, 2022
Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
March 25, 2021